DK2623592T3 - Anti-humane ccr7-antistoffer, hybridom, medicinsk sammensætning og antistof-immobiliseret bærer - Google Patents

Anti-humane ccr7-antistoffer, hybridom, medicinsk sammensætning og antistof-immobiliseret bærer Download PDF

Info

Publication number: DK2623592T3
Authority: DK; Denmark
Prior art keywords: hybridom; medical composition; antibody immobilized; immobilized carrier; human ccr7
Prior art date: 2010-09-28

Application number

DK11829086.5T

Other languages

English (en)

Inventor

Naoki Nishiguchi

Masahiro Furutani

Akiyoshi Hirayama

Tatsuo Shimizu

Kiyoshi Takayama

Tomoko Shimizu

Kazuya Suzuki

Original Assignee

Nb Health Laboratory Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-09-28

Filing date

2011-09-27

Publication date

2019-08-19

2011-09-27 Application filed by Nb Health Laboratory Co Ltd filed Critical Nb Health Laboratory Co Ltd

2019-08-19 Application granted granted Critical

2019-08-19 Publication of DK2623592T3 publication Critical patent/DK2623592T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Cardiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Virology (AREA)
Oncology (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Biotechnology (AREA)
Diabetes (AREA)
Dermatology (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Urology & Nephrology (AREA)
Zoology (AREA)
Rheumatology (AREA)
Wood Science & Technology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Communicable Diseases (AREA)
Vascular Medicine (AREA)

DK11829086.5T 2010-09-28 2011-09-27 Anti-humane ccr7-antistoffer, hybridom, medicinsk sammensætning og antistof-immobiliseret bærer DK2623592T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2010217096		2010-09-28
PCT/JP2011/072014 WO2012043533A1 (ja)	2010-09-28	2011-09-27	抗ヒトｃｃｒ７抗体、ハイブリドーマ、核酸、ベクター、細胞、医薬組成物、並びに、抗体固定化担体

Publications (1)

Publication Number	Publication Date
DK2623592T3 true DK2623592T3 (da)	2019-08-19

Family

ID=45892974

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK11829086.5T DK2623592T3 (da)	2010-09-28	2011-09-27	Anti-humane ccr7-antistoffer, hybridom, medicinsk sammensætning og antistof-immobiliseret bærer

Country Status (11)

Country	Link
US (3)	US8865170B2 (da)
EP (1)	EP2623592B1 (da)
JP (2)	JP5315495B2 (da)
KR (1)	KR101886890B1 (da)
CN (2)	CN103261412B (da)
AU (1)	AU2011309114B2 (da)
CA (1)	CA2813203C (da)
DK (1)	DK2623592T3 (da)
IL (1)	IL225461B (da)
NZ (1)	NZ609154A (da)
WO (1)	WO2012043533A1 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2013184200A1 (en) *	2012-06-05	2013-12-12	Msm Protein Technologies	Human monoclonal antibodies against human chemokine receptor ccr7
JP6469644B2 (ja) *	2013-03-15	2019-02-13	アムジエン・インコーポレーテツド	抗ｃｃｒ７抗原結合タンパク質に関係する方法および組成物
EP3023435A1 (en) *	2014-11-19	2016-05-25	Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.	Influenza virus binding peptides
JP6449110B2 (ja) *	2015-06-15	2019-01-09	マブチモーター株式会社	ロータ、モータおよびロータの製造方法
CA2994214C (en)	2015-08-10	2024-03-12	Pepmab B.V.	Humanized anti-ccr7 receptor antibodies
JOP20190187A1 (ar) *	2017-02-03	2019-08-01	Novartis Ag	مترافقات عقار جسم مضاد لـ ccr7
US10397821B2 (en) *	2017-03-07	2019-08-27	Itron Networked Solutions, Inc.	Reduced latency operating modes for wireless mesh networks
WO2020127509A1 (en)	2018-12-18	2020-06-25	Catapult Therapeutics B.V.	The use of anti-ccr7 mabs for the prevention or treatment of graft-versus-host disease (gvhd)
US11357787B2 (en)	2019-02-18	2022-06-14	Nb Health Laboratory Co., Ltd.	Method for selecting cells, method for producing nucleic acid, method for producing recombinant cells, method for producing target substance, method for producing pharmaceutical composition, and reagent
CN112957472B (zh) *	2021-02-05	2021-11-16	无锡市第五人民医院	靶向ccl19/ccr7的乙型肝炎免疫治疗剂及其用途
KR20250084918A (ko)	2022-10-18	2025-06-11	가부시키가이샤 에누비 켄코우겡큐쇼	항체, 핵산, 세포 및 의약
WO2024194605A1 (en)	2023-03-17	2024-09-26	Quell Therapeutics Limited	Treg therapy
WO2024204440A1 (ja) *	2023-03-28	2024-10-03	株式会社エヌビィー健康研究所	抗体、核酸、細胞、及び医薬
CN119390838B (zh) *	2024-05-29	2025-06-10	锐胜科生物医药(上海)有限公司	一种靶向ccr7的纳米抗体及其制备与应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
IE52535B1 (en)	1981-02-16	1987-12-09	Ici Plc	Continuous release pharmaceutical compositions
HUT35524A (en)	1983-08-02	1985-07-29	Hoechst Ag	Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4945050A (en)	1984-11-13	1990-07-31	Cornell Research Foundation, Inc.	Method for transporting substances into living cells and tissues and apparatus therefor
EP1136556B1 (en)	1991-11-25	2005-06-08	Enzon, Inc.	Method of producing multivalent antigen-binding proteins
PT584348E (pt)	1992-03-11	2005-10-31	Powderject Vaccines Inc	Vacina genetica para virus da imunodeficiencia
US5612030A (en) *	1995-01-17	1997-03-18	University Of Kentucky Research Foundation	Anti-idiotype monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
US20020168358A1 (en)	2001-04-30	2002-11-14	Gladue Ronald P.	Treatment of T-cell mediated diseases
WO2004104574A2 (en)	2003-05-23	2004-12-02	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 7 (ccr7)
KR101215780B1 (ko)	2004-10-15	2012-12-26	죠 지바	동물의 면역 방법, 면역용 조성물, 항체의 제조 방법,하이브리도마의 제조 방법 및 모노클로날 항체의 제조 방법
WO2007003216A1 (en) *	2005-07-06	2007-01-11	Universidad Autónoma de Madrid	Anti-ccr7 receptor antibodies for the treatment of cancer
US8795668B2 (en)	2005-12-23	2014-08-05	The Regents Of The University Of Michigan	Methods for treating pulmonary fibrosis
BRPI0712850A8 (pt) *	2006-06-07	2018-05-02	Bioalliance Cv	anticorpos que reconhecem um epitopo contendo carboidrato em cd-43 e cea expressados em células cancerígenas e métodos de uso dos mesmos
EP2050466B1 (en)	2006-08-14	2015-10-28	Chugai Seiyaku Kabushiki Kaisha	Diagnosis and treatment of cancer using anti-desmoglein-3 antibodies
CA2672581A1 (en)	2006-12-14	2008-06-19	Forerunner Pharma Research Co., Ltd.	Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same
WO2009139853A2 (en) *	2008-05-14	2009-11-19	Kim, Eldar	Human monoclonal antibodies against human chemokine receptor ccr7

2011
- 2011-09-27 JP JP2012536465A patent/JP5315495B2/ja active Active
- 2011-09-27 NZ NZ609154A patent/NZ609154A/en unknown
- 2011-09-27 CN CN201180056955.3A patent/CN103261412B/zh active Active
- 2011-09-27 WO PCT/JP2011/072014 patent/WO2012043533A1/ja not_active Ceased
- 2011-09-27 KR KR1020137010575A patent/KR101886890B1/ko active Active
- 2011-09-27 AU AU2011309114A patent/AU2011309114B2/en active Active
- 2011-09-27 DK DK11829086.5T patent/DK2623592T3/da active
- 2011-09-27 CA CA2813203A patent/CA2813203C/en active Active
- 2011-09-27 EP EP11829086.5A patent/EP2623592B1/en active Active
- 2011-09-27 US US13/876,265 patent/US8865170B2/en active Active
- 2011-09-27 CN CN201610098810.4A patent/CN105884895B/zh active Active
2012
- 2012-11-30 JP JP2012262162A patent/JP2013059343A/ja not_active Withdrawn
2013
- 2013-03-24 IL IL225461A patent/IL225461B/en active IP Right Grant
2014
- 2014-09-18 US US14/489,918 patent/US20150017167A1/en not_active Abandoned
- 2014-09-18 US US14/489,898 patent/US9505844B2/en active Active

Also Published As

Publication number	Publication date
EP2623592A4 (en)	2014-05-14
CN105884895A (zh)	2016-08-24
US8865170B2 (en)	2014-10-21
KR20130119923A (ko)	2013-11-01
JP5315495B2 (ja)	2013-10-16
US9505844B2 (en)	2016-11-29
IL225461B (en)	2019-08-29
KR101886890B1 (ko)	2018-08-08
US20150010998A1 (en)	2015-01-08
NZ609154A (en)	2014-10-31
CA2813203A1 (en)	2012-04-05
IL225461A0 (en)	2013-06-27
WO2012043533A1 (ja)	2012-04-05
AU2011309114B2 (en)	2015-03-19
CN103261412B (zh)	2016-03-23
EP2623592A1 (en)	2013-08-07
EP2623592B1 (en)	2019-05-15
CA2813203C (en)	2022-10-18
AU2011309114A8 (en)	2013-09-05
AU2011309114A1 (en)	2013-05-02
JPWO2012043533A1 (ja)	2014-02-24
CN105884895B (zh)	2019-12-13
CN103261412A (zh)	2013-08-21
JP2013059343A (ja)	2013-04-04
US20130195869A1 (en)	2013-08-01
US20150017167A1 (en)	2015-01-15

Publication	Publication Date	Title
DK2623592T3 (da)	2019-08-19	Anti-humane ccr7-antistoffer, hybridom, medicinsk sammensætning og antistof-immobiliseret bærer
IL262073B (en)	2020-11-30	Antibody drug conjugates (adc) that bind to 191p4d12 proteins
PL3789038T3 (pl)	2023-01-23	Humanizowane i chimeryczne przeciwciała monoklonalne wobec cd47
IL250691A0 (en)	2017-04-30	Anti-ox40 antibodies and methods of using them
ZA201207211B (en)	2014-06-25	Antibodies with ph dependent antigen binding
DK2624866T3 (da)	2022-09-05	Tumorspecifikke antistoffer og anvendelser deraf
SI2510011T1 (sl)	2014-12-31	Monoklonska protitelesa, ki veĹľejo B7H6 in njihova uporaba
EP2501724A4 (en)	2013-11-06	MONOCLONAL ANTIBODIES AND DIAGNOSTIC USES THEREOF
IL222359A0 (en)	2012-12-31	Monoclonal antibodies against her2 antigens, and uses therefor
ZA201300573B (en)	2014-03-26	Anti-tumor antigen antibodies and methods of use
HRP20170983T1 (hr)	2017-09-22	Pripravci s visokom koncentracijom antitijela
EP2566890A4 (en)	2013-11-20	ANTI-PAI-1 ANTIBODIES AND METHOD FOR THEIR USE
SMT201700083B (it)	2017-03-08	Anticorpi monoclonali
FI20075278A0 (fi)	2007-04-20	Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
PL2542575T3 (pl)	2017-06-30	Ekspresja przeciwciał monoklonalnych u tetrahymena
ZA201304459B (en)	2019-11-27	Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
PL2621955T3 (pl)	2018-07-31	Przeciwciała anty-CEACAM6 i ich zastosowania
LT3345615T (lt)	2020-02-10	Optimizuoti monokloniniai antikūnai prieš audinių faktoriaus kelio slopiklį (tfpi)
EP2545075A4 (en)	2014-01-22	HUMANIZED AND CHIMERIC ANTIBODIES AGAINST PROPERDIN
EP2650367A4 (en)	2015-07-08	HUMAN MONOCLONAL ANTIBODY
IL238920A0 (en)	2015-07-30	Human monoclonal antibodies against activated protein c and their uses
EP2659273A4 (en)	2015-07-01	MONOCLONAL ANTIBODIES TO ALPHA-ACTININ-4-ANTIGENS AND THEIR USE
EP2484694A4 (en)	2013-05-01	MONOCLONAL ANTIBODY AGAINST HUMAN H1G1 POLYPEPTIDE
WO2011116014A9 (en)	2012-02-16	Humanized antibodies to labyrinthin and uses thereof
EP2540742A4 (en)	2014-02-12	MONOCLONAL ANTIBODIES OF ANTI-CYR61 PROTEIN AND USES THEREOF